Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study
N Okada, R Matsuoka, T Sakurada, M Goda… - Scientific reports, 2020 - nature.com
Immune checkpoint inhibitors (ICIs) elicit antitumour effects by activating the host immunity
and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI …
and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI …
Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer
A Yamagata, T Yokoyama, Y Fukuda… - Cancer Chemotherapy and …, 2021 - Springer
Purpose Immune checkpoint inhibitor-associated interstitial lung disease (ICI-ILD) is a
serious immune-related adverse event. We aimed to evaluate the impact of ICI-ILD severity …
serious immune-related adverse event. We aimed to evaluate the impact of ICI-ILD severity …
Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
T Sugano, M Seike, Y Saito, T Kashiwada… - Thoracic …, 2020 - Wiley Online Library
Background Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is
a potentially life‐threatening adverse event. The purpose of this study was to evaluate …
a potentially life‐threatening adverse event. The purpose of this study was to evaluate …
Association of preexisting interstitial lung abnormalities with immune checkpoint inhibitor–induced interstitial lung disease among patients with nonlung cancers
K Shimoji, T Masuda, K Yamaguchi… - JAMA Network …, 2020 - jamanetwork.com
Importance Immune checkpoint inhibitor–induced interstitial lung disease (ICI-ILD) is
clinically serious and life-threatening. Preexisting interstitial lung abnormalities have been …
clinically serious and life-threatening. Preexisting interstitial lung abnormalities have been …
Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer
Y Nakanishi, T Masuda, K Yamaguchi… - Respiratory …, 2019 - Elsevier
Background Approximately 5% of non-small cell lung cancer (NSCLC) patients develop
immune checkpoint inhibitor (ICI)-induced interstitial lung disease (ICI-ILD), 10% of whom …
immune checkpoint inhibitor (ICI)-induced interstitial lung disease (ICI-ILD), 10% of whom …
Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease
Y Tasaka, T Honda, N Nishiyama, T Tsutsui, H Saito… - Lung Cancer, 2021 - Elsevier
Objectives The efficacy of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer
(NSCLC) patients with pre-existing interstitial lung disease (ILD) is unclear. Materials and …
(NSCLC) patients with pre-existing interstitial lung disease (ILD) is unclear. Materials and …
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
M Delaunay, J Cadranel, A Lusque… - European …, 2017 - Eur Respiratory Soc
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) …
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) …
[HTML][HTML] Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study
Y Suzuki, M Karayama, T Uto, M Fujii, T Matsui… - Journal of Thoracic …, 2020 - Elsevier
Introduction Programmed cell death protein 1 immune checkpoint inhibitors (ICIs) have been
reported to improve the survival of patients with NSCLC. On the expansion of clinical …
reported to improve the survival of patients with NSCLC. On the expansion of clinical …
Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: a systematic …
M Zhang, Y Fan, L Nie, G Wang, K Sun, Y Cheng - Chest, 2022 - Elsevier
Background Patients with non-small cell lung cancer (NSCLC) and preexisting interstitial
lung disease (ILD) are often excluded from clinical trials of immune checkpoint inhibitors …
lung disease (ILD) are often excluded from clinical trials of immune checkpoint inhibitors …
Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China
Y Shi, J Fang, C Zhou, A Liu, Y Wang, Q Meng… - Thoracic …, 2022 - Wiley Online Library
Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for
advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly …
advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly …
相关搜索
- checkpoint inhibitor lung disease
- checkpoint inhibitor risk factors
- risk factors lung disease
- adverse events lung cancer
- checkpoint inhibitors meta analysis
- meta analysis lung cancer
- checkpoint inhibitors patients with nsclc
- checkpoint inhibitor adverse events
- cancer patients lung disease
- risk factors adverse events
- risk factors meta analysis
- checkpoint inhibitor management practices
- clinical outcomes lung diseases
- management practices lung cancer
- checkpoint inhibitor lung cancer
- risk factors lung cancer